Relationship between clinical remission of perianal fistulas in Crohn’s disease and serum adalimumab concentrations: A multi-center cross-sectional study

Table 2 Characteristics of perianal fistulas at each visit according to the presence of clinical remission

	Clinical remission, n (%) unless otherwise specified
	No, n = 34	Yes, n = 22
PAF duration (Time from fistula diagnosis to date of visit) in mo, Med [IQR]	12 [8-23.5]	53.5 [32.75-81.75]
Drainage duration (Time from seton setting down to date of visit) in mo, Med [IQR]	9 [4.75-17]	8 [4-19]
Combination therapy (with methotrexate or thiopurine)	23 (68%)	7 (32%)
Optimization	19 (56%)	14 (64%)
Serum concentrations of ADA (μg/mL), Med [IQR]	10.7 [2.4-14.7]	14.1 [9.8-16]
C reactive protein (mg/L), Med [IQR]	2.7 [0.07-15.25]	0.9 [0-1.8]
Serum albumin (g/L), Med [IQR]	42 [38.25-47.3]	43 [41.85-44.25]
Length of treatment by ADA in mo, Med [IQR]	12 [6-34.75]	37.5 [23.75-46.75]

PAF: Perianal fistulas; Med: Median; ADA: Adalimumab.